News|Articles|October 9, 2025
Streamline AAV-based Gene Therapies with High-Performing Off-the-Shelf Plasmids
Author(s)Catalent
Key Takeaways
Optimized plasmids are vital for viral vector production. Catalent’s off-the-shelf plasmids help AAV gene therapy developers enhance efficiency, reduce costs, and improve consistency across development and manufacturing.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Report - Digital Transformation in Biopharma: The Gap Between Hype and Implementation
2
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
3
How Big Biopharma Investment in CGTs Will Redefine the Industry Pipeline
4
Streamline AAV-based Gene Therapies with High-Performing Off-the-Shelf Plasmids
5
